Eighty-Nine Percent of Surveyed Rheumatologists Say They Will Prescribe Roche/Chugai's Actemra for Rheumatoid... (til more clinical data becomesavailable....)

Eighty-Nine Percent of Surveyed Rheumatologists Say They Will Prescribe Roche/Chugai's Actemra for Rheumatoid Arthritis

Date:8/6/2008

til more clinical data becomes available.

Nevertheless, surveyed rheumatologists remain steadfast in their preference for TNF-alpha inhibitors over other biologic agents for the treatment of rheumatoid arthritis. Ninety-nine of 100 surveyed rheumatologists reported prescribing TNF-alpha inhibitors as first-line biologic therapy for the disease.

"Most rheumatologists expect the dominance of TNF-alpha inhibitors to continue, and possibly expand, over the next two years," said Cindy Mundy, Ph.D., director at Decision Resources. "The upcoming launches of Cimzia and golimumab will increase the number of TNF-alpha inhibitors approved for rheumatoid arthritis from three to five. Following the launches of Cimzia and golimumab, nearly half of surveyed rheumatologists expect to prescribe three or more TNF-alpha inhibitors before moving to a different class of agents."

Biologics in Rheumatoid Arthritis: Physician and Payer Perspective on Recently Launched and Emerging Biologics in Rheumatoid Arthritis is based on a U.S. survey of 100 rheumatologists and 20 MCO pharmacy directors. Their responses were compared to assess similarities and differences of opinion regarding clinical, economic and scientific factors.

About Physician & Payer Forum

Physician & Payer Forum is a primary research service from Decision Resources that offers access to high volume-prescribing physicians, specialists, and managed care organization representatives in the United States; analysis of events and survey participants' responses to them; insight into prescribing patterns; and an examination of the implications of events and issues for the pharmaceutical market.

About Decision Resources

Decision Resources (http://www.decisionresources.com) is a world leader in market research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master
'/>"/>

0

GOOD

Page: 1 2 3
Related medicine news :

1. Thoratec Reports 44 Percent Increase in Second Quarter Revenues;
2. Mothers from affluent neighborhoods near highways increase odds of low weight babies by 81 percent
3. A High-Density Lipoprotein Raising Drug That Has a Lower Discontinuation Rate Than That of Extended Release Niaspan Would Earn a 20 Percent Patient Share in the Dyslipidemia Drug Market
4. Medco Reports Record Second-Quarter 2008 GAAP Diluted EPS; Reflects Growth of 34.2 Percent; Raises and Narrows 2008 Guidance
5. Galderma announces approval for Differin gel 0.1 percent in Japan
6. 89 percent of childrens food products provide poor nutritional quality
7. Statement on CDC Announcement That 70 Percent of the U. S. Population Now Receives Optimally Fluoridated Water By Mark J. Feldman, DMD, President, American Dental Association
8. Cadaver tissue fails nearly 25 percent of the time in young ACL reconstructions
9. Primary Care Physicians Prescriptions of Aricept for Alzheimers Disease Will Drop by 20 Percent Following the Availability of Generic Razadyne in December 2008
10. Disaboom Survey Reveals 52 Percent of Americans Would Rather be Dead Than Disabled
11. Economist Finds Highmark/IBC Merger Would Result in 70 Percent Share in Pennsylvania, Far Higher Than Initial Reports

Post Your Comments:

Eighty-Nine Percent of Surveyed Rheumatologists Say They Will Prescribe Roche/Chugai's Actemra for Rheumatoid...(til more clinical data becomesavailable....),Health